Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8045039 | 0.77 | RARB (0.35) | PDK2ALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL8062997 | 0.73 | PIK3CA (0.34) | PKMPDK2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL522786 | 0.68 | CA12 (0.47) | PDK2ALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL8062941 | 0.67 | KDM4E (0.35) | PDK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL8058138 | 0.65 | KDM4E (0.36) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL8058193 | 0.65 | VEGFA (0.41) | PKMPDK2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL410165 | 0.65 | ALPL (0.45) | PKMPDK2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL8058195 | 0.64 | CFTR (0.39) | PDK2MAPT | |
| SCHEMBL8060665 | 0.64 | ALDH1A1 (0.36) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL8045342 | 0.64 | ALDH1A1 (0.33) | PKMPDK2ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489233-B1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | NR3C2, CRHR2, TPH2 | PKM 3536/4885PDK2 309/4885ALDH1A1 1366/4885 |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | NR3C2, CRHR2, TPH2 | PKM 3536/4885PDK2 309/4885ALDH1A1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.